Recent News

Viral Vaccine Development Gets Major Boost From xCELLigence RTCA December 14, 2017Using xCELLigence Real-Time Cell Analysis (RTCA), Sanofi Pasteur scientists have developed an assay for accurate viral titer determination that is 5-times less labor intensive and 3.5-times cheaper than conventional methods Accurate determination of viral titers is critical to vaccine development. Historically, titers have been determined using endpoint assays which are labor-intensive, expensive, and time consuming. This is increasingly problematic in ... Read More
Asthma Intervention: Novel Impedance-Based Assay Monitors the Contraction and Relaxation of Smooth Muscle Cells and Fibroblasts in Real-Time December 12, 2017Using xCELLigence Real-Time Cell Analysis (RTCA) scientists at Genentech have developed an automated and high throughput assay for studying the molecular determinants of bronchoconstriction/dilation Contraction and relaxation of smooth muscle cells and fibroblasts within the bronchial airways dramatically affects airflow, and being able to modulate these processes is critical for treating asthma and allergic responses.  Citing that the traditional assay for ... Read More
Oncolytic Adenovirus Expressing BiTE Effectively Recruits T Cells to Kill Diverse Cancer Cell Types December 8, 2017By expressing a secreted form of an EpCAM-specific BiTE molecule in the cancer cells it infects, a novel oncolytic virus both kills cells directly and induces a robust cytotoxic T cell response. In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two ... Read More
ACEA Biosciences and Ncardia announce global partnership to provide solutions for cardiac drug discovery and cardiac safety assessment November 30, 2017ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership to provide comprehensive solutions for cardiac drug discovery and cardiac safety assessment. This multifaceted partnership will include the joint ... Read More
Characterizing Bacteriophage-Derived Enzymes That Degrade Staphylococcus Biofilms October 20, 2017Employing the xCELLigence® technology from ACEA Biosciences, a team of Spanish scientists have developed a real-time assay for screening anti-biofilm treatments and quantifying their efficacy Biofilms are surface-attached communities of bacterial or fungal cells that are enmeshed in an extensive extracellular matrix which makes them more resistant to both antibiotics and the immune system. With biofilms estimated to be responsible ... Read More
View all News

  Upcoming Events

ASCB 2017 | December 2-6 | Philadelphia, PA.Our team members are at ASCB in Philadelphia on December 2-6! Come visit our booth #610 to learn more about our xCELLigence and NovoCyte instruments.Read More
World Vaccine Congress 2017 | November 30 – December 1 | San Diego, CA.Come visit our table at World Vaccine Congress in San Diego (Nov 30 – Dec 1)! This event will offer learning and business development opportunities taking advantage of the rich biotech and funding environment that the west coast offers.Read More
SITC 2017 | November 8-12 | National Harbor, MD.Join ACEA Booth #734 at the Society for Immunotherapy of Cancer (SITC) for our 32nd Annual Meeting & Pre-Conference Programs Nov. 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Md. This conference is known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy field, this is the conference you don’t ... Read More
View all Events

  ACEA Newsletter

Sign up for the ACEA Newsletter.

View ACEA Newsletters